Prevalence of marijuana use in pregnant women with concurrent opioid use disorder or alcohol use in pregnancy

Table 3 Prevalence of marijuana use during pregnancy by MOUD and other substance exposures stratified by study group (N = 251)

Co-exposures	OUD (n = 125)		OUD + alcohol (n = 57)		Alcohol (n = 69)
Co-exposures	Marijuana use (n = 54)	No Marijuana use (n = 71)	Marijuana use (n = 30)	No Marijuana use (n = 27)	Marijuana use (n = 32)	No marijuana use (n = 37)
	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)
Type of MOUD					–	–
Methadone	18 (37.5)	30 (62.5)	9 (42.9)	12 (57.1)	–	–
Buprenorphine	33 (45.8)	39 (54.2)	21 (58.3)	15 (41.7)	–	–
Methadone and buprenorphine	3 (60.0)	2 (40.0)	0 (0.0)	0 (0.0)	–	–
Other opioids^a
Heroin	25 (49.0)	26 (51.0)	14 (56.0)	11 (44.0)	–	–
Opioid analgesics^b	16 (53.3)	14 (46.7)	11 (52.4)	10 (47.6)	5 (55.6)	4 (44.4)
Opiates detected by UDS only	1 (50.0)	1 (50.0)	0 (0.0)	2 (100.0)	–	–
Polysubstance use^c	25 (55.6)	20 (44.4)	17 (58.6)	12 (41.4)	10 (58.8)	7 (41.2)
Tobacco use	48 (47.1)	54 (52.9)	27 (54.0)	23 (46.0)	14 (56.0)	11 (44.0)

	Mean (SD)	Mean (SD)	Mean (SD)	Mean (SD)	Mean (SD)	Mean (SD)
Average ounces of alcohol per day, LMP to Visit 1^d	0.0 (0.0)	0 (0.0)	1.0 (1.6)	0.7 (1.1)	1.3 (2.2)	0.6 (1.5)
AUDIT score¹	1.1 (1.7)	0.6 (1.0)	11.8 (8.4)	15.6 (10.9)	14.2 (8.1)	10.3 (9.0)

OUD opioid use disorder, GED General Educational Development, MOUD medication for opioid use disorder, UDS urine drug screen, LMP last menstrual period
^aCategories are not mutually exclusive
^bOpioid analgesic use in the Alcohol group was directed by a physician and did not constitute misuse
^cPolysubstance use defined as using at least one other substance including: stimulants, benzodiazepines, sedatives, prescription medications (Soma/Carisoprodol), or hallucinogens
^dAverage absolute ounces of alcohol per day across two 30-day timeline follow-back (TLFB) calendars
¹p < 0.01 (Wald test from logistic regression model for the interaction between the AUDIT score and group classification)

ISSN: 1940-0640